![Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials - The Lancet ... Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials - The Lancet ...](https://www.thelancet.com/cms/asset/ecfb826f-3167-44f1-b634-61dedd97b4e5/gr1.jpg)
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials - The Lancet ...
![China to overtake 56 nations by 2025 in per capita income surge | Business and Economy News | Al Jazeera China to overtake 56 nations by 2025 in per capita income surge | Business and Economy News | Al Jazeera](https://www.aljazeera.com/wp-content/uploads/2020/11/east.jpg?w=770&resize=770%2C538)
China to overtake 56 nations by 2025 in per capita income surge | Business and Economy News | Al Jazeera
![China to overtake 56 nations by 2025 in per capita income surge | Business and Economy News | Al Jazeera China to overtake 56 nations by 2025 in per capita income surge | Business and Economy News | Al Jazeera](https://www.aljazeera.com/wp-content/uploads/2020/11/rp.jpg?w=770&resize=770%2C493)